Parkinson’s disease Archives

Comic-style illustration of Michael J. Fox pointing toward Parkinson’s research and clinical trial displays, surrounded by scientists, patients and investors, with upward arrows symbolizing progress and investor optimism.

The Michael J. Fox Foundation Is Building Parkinson’s Next Chapter. Investors Have Reason to Pay Attention. -( $ABBV $IBB $SER $XBI )

by John F. Heerdink, Jr. 2 days ago 167Views 0Likes

Better biomarkers, new FDA approvals and an emerging delivery pipeline strengthen the case for Parkinson’s innovation, with AbbVie and Serina Therapeutics offering distinct investment angles. The most compelling Parkinson’s investment story does not begin with a stock chart. It begins with a…

Investor-focused healthcare graphic showing a laboratory scene, a clinician holding a drug-delivery device, a glowing brain illustration, molecular imagery and a city skyline. The image highlights AbbVie Inc. (NYSE: ABBV) receiving FDA approval for JUVMO (tavapadon) for Parkinson’s disease and positions Serina Therapeutics Inc. (NYSE American: SER) and its SER-252 program as a potential next-generation therapy opportunity in advanced Parkinson’s disease.

AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI )

by John F. Heerdink, Jr. September 29, 2026 412Views 0Likes

AbbVie Inc. (NYSE: ABBV) has secured (Sept. 28) FDA approval for JUVMO™ (tavapadon), a new once-daily Parkinson’s therapy, adding an important fresh option to a market long defined by the delicate art of managing motor symptoms, “OFF” time, dyskinesia and medication burden. For Serina…

Promotional graphic for Tribe Public’s CEO presentation and Q&A webinar, “A New Approach to Advanced Parkinson’s Disease: Exploring SER-252’s Clinical Progress,” featuring Serina Therapeutics CEO Steven Ledger; September 24, 2026, at 8:30 a.m. PT / 11:30 a.m. ET.

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

by John F. Heerdink, Jr. September 23, 2026 181Views 0Likes

Parkinson’s disease is one of medicine’s most stubborn commercial and scientific frontiers, and Serina Therapeutics, Inc. (NYSE American: SER) is positioning its lead program, SER-252, squarely in the middle of that opportunity. The clinical-stage biotechnology company has opened registration for a Tribe Public CEO…

Illustration of a bullish investment landscape showing AI-powered ecommerce, healthcare innovation, cybersecurity and market growth. Robots manage online-shopping fulfillment around an ecommerce screen, clinicians and researchers work in a modern medical setting, and professionals point toward rising stock charts and upward arrows, with the phrases “AI Commerce,” “Healthcare” and “Stay Engaged.”

A Resilient Economy, AI Commerce & Healthcare Catalysts Give Many More Than One Reason to Stay Engaged -( $AMWL $AMZN $APPL $CRWD $GOOG $OKTA $PANW $PYPL $SER $SHOP $SMWB $XYZ $ZS )

by John F. Heerdink, Jr. September 14, 2026 428Views 0Likes

Many entered the week bracing for a Federal Reserve rate hike, yet the more constructive takeaway may be that policy makers still have room to choose patience. That possibility, alongside fresh evidence of AI-led ecommerce change, government-scale digital-health demand and advancing biotech milestones,…

Illustration of an older man with Parkinson’s symptoms beside a laboratory researcher holding a syringe, with a large brain diagram showing dopamine pathways, sustained drug release, motor control, and Serina Therapeutics’ Parkinson’s disease drug-delivery innovation.

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

by John F. Heerdink, Jr. September 8, 2026 289Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) is building a potentially compelling clinical and platform-driven story around a familiar biotech proposition: take a medicine with demonstrated utility, improve the way it behaves in the body, and create a product patients may find meaningfully…

“Is The Beaten Down Biotech Sector The Smartest Bet In Today’s Volatile Market?” – ( $SER $XBI $IBB $PFE )

by John F. Heerdink, Jr. June 16, 2025 550Views 0Likes

In the bustling digital amphitheater of Tribe Public’s latest CEO Presentation, the question of the hour was as sharp as it was timely: “Is the beaten down biotech sector the smartest bet in today’s volatile market?” With a flourish of slides and…

Tag: Parkinson’s disease

The Michael J. Fox Foundation Is Building Parkinson’s Next Chapter. Investors Have Reason to Pay Attention. -( $ABBV $IBB $SER $XBI )

AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI )

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

A Resilient Economy, AI Commerce & Healthcare Catalysts Give Many More Than One Reason to Stay Engaged -( $AMWL $AMZN $APPL $CRWD $GOOG $OKTA $PANW $PYPL $SER $SHOP $SMWB $XYZ $ZS )

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

“Is The Beaten Down Biotech Sector The Smartest Bet In Today’s Volatile Market?” – ( $SER $XBI $IBB $PFE )

Your Guide To Staying Informed In The Markets